A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103) : Annals of Surgery

Journal Logo

PAPERS CHOSEN FOR PRESENTATION AT THE 2020 ANNUAL MEETING OF THE AMERICAN SURGICAL ASSOCIATION

A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI)

Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103)

Bulger, Eileen M. MD; May, Addison K. MD; Robinson, Bryce R. H. MD; Evans, David C. MD; Henry, Sharon MD§; Green, John M. MD; Toschlog, Eric MD||; Sperry, Jason L. MD∗∗; Fagenholz, Peter MD††; Martin, Niels D. MD‡‡; Dankner, Wayne M. MD§§; Maislin, Greg PhD¶¶; Wilfret, David MD§§; Bernard, Andrew C. MD||||; on behalf of the ACCUTE Study Investigators∗∗∗

Author Information
Annals of Surgery 272(3):p 469-478, September 2020. | DOI: 10.1097/SLA.0000000000004102

Abstract

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid